Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...

The transaction is a big splash for Merck KGaA, representing the company’s largest deal since its buyout of Sigma-Aldrich for ...

Bio-Techne Corp, has agreed to an acquisition offer by Germany’s Merck KGaA for about $11.3 billion, the largest M&A deal ...

By Padmanabhan Ananthan and Christy Santhosh June 25 (Reuters) - German drugmaker Merck KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne Corp for $11.3 billion, its largest deal in ...

Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

Merck KGaA agreed to buy Bio-Techne Corporation for $11.3 billion to bolster its life-science business, marking the German ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based ...

Germany's Merck KGaA has announced a major acquisition agreement to buy U.S.-based life sciences company Bio-Techne Corp ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest ...